autologous crispr-cas9 engineered regnase-1/socs1 dual-edited tumor infiltrating lymphocytes ksq-004ex
Generic: Autologous CRISPR-Cas9 Engineered Regnase-1/SOCS1 Dual-edited Tumor Infiltrating Lymphocytes KSQ-004EX
autologous crispr-cas9 engineered regnase-1/socs1 dual-edited tumor infiltrating lymphocytes ksq-004ex: 1 clinical trial tracked.
autologous crispr-cas9 engineered regnase-1/socs1 dual-edited tumor infiltrating lymphocytes ksq-004ex evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous crispr-cas9 engineered regnase-1/socs1 dual-edited tumor infiltrating lymphocytes ksq-004ex, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Primary endpoint: Safety and adverse events (AEs)
Interventionalopen141 targetStarted 2024-11Completion 2041-081 site · United StatesM.D. Anderson Cancer Center